Interpace Biosciences, Inc.
IDXG
$0.9077
-$0.0823-8.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.23M | 11.52M | 12.32M | 12.30M | 12.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.23M | 11.52M | 12.32M | 12.30M | 12.04M |
| Cost of Revenue | 3.96M | 4.15M | 3.40M | 4.79M | 4.24M |
| Gross Profit | 5.28M | 7.37M | 8.92M | 7.51M | 7.81M |
| SG&A Expenses | 5.57M | 5.36M | 5.65M | 5.40M | 5.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.70M | 9.69M | 9.24M | 10.39M | 9.41M |
| Operating Income | -468.00K | 1.83M | 3.07M | 1.91M | 2.63M |
| Income Before Tax | -533.00K | 1.77M | 2.87M | 1.37M | 2.52M |
| Income Tax Expenses | -- | 18.00K | -8.00K | 4.00K | 4.00K |
| Earnings from Continuing Operations | -533.00K | 1.75M | 2.88M | 1.36M | 2.51M |
| Earnings from Discontinued Operations | -107.00K | -107.00K | 16.00K | -82.00K | -74.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -640.00K | 1.65M | 2.89M | 1.28M | 2.44M |
| EBIT | -468.00K | 1.83M | 3.07M | 1.91M | 2.63M |
| EBITDA | -367.00K | 1.92M | 3.17M | 1.99M | 2.70M |
| EPS Basic | -0.14 | 0.37 | 0.55 | 0.29 | 0.56 |
| Normalized Basic EPS | -0.08 | 0.25 | 0.41 | 0.19 | 0.36 |
| EPS Diluted | -0.14 | 0.06 | 0.05 | 0.29 | 0.55 |
| Normalized Diluted EPS | -0.08 | 0.04 | 0.04 | 0.19 | 0.36 |
| Average Basic Shares Outstanding | 4.42M | 4.42M | 4.41M | 4.39M | 4.38M |
| Average Diluted Shares Outstanding | 4.42M | 27.70M | 49.72M | 4.42M | 4.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |